# PIC1 Injection Therapy for Relapsed/Refractory B-NHL

> **NCT07456371** · PHASE1 · RECRUITING · sponsor: **Chongqing Precision Biotech Co., Ltd** · enrollment: 18 (estimated)

## Conditions studied

- Non-Hodgkin Lymphoma

## Interventions

- **BIOLOGICAL:** PIC1 Injection

## Key facts

- **NCT ID:** NCT07456371
- **Lead sponsor:** Chongqing Precision Biotech Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03
- **Primary completion:** 2026-12
- **Final completion:** 2029-02
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2026-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07456371

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07456371, "PIC1 Injection Therapy for Relapsed/Refractory B-NHL". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT07456371. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*